ArticleBioFactors (Oxford, England)
Growth Differentiation Factor 15 (GDF15) Protects Against Sepsis-Associated Acute Kidney Injury via Suppression of TLR4-MyD88-NF-κB Signaling and Ferroptosis.
Article in BioFactors (Oxford, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated acute kidney injury (SAKI) lacks mechanism-based therapies, with upstream ferroptosis regulators undefined. This study investigated growth differentiation factor 15 (GDF15) as a suppressor of TLR4-MyD88-NF-κB signaling and associated ferroptosis. Differential GDF15 expression was identified by integrated analysis of three GEO datasets (GSE232404, GSE30718, GSE44925) and validated in SAKI patient kidney tissue (n = 30 vs. controls n = 25) and in kidneys from cecal ligation and puncture (CLP) mice. CLP mice received recombinant GDF15 (rmGDF15) (50 ng/kg ip); renal function (Scr/BUN), histology, kidney injury molecule-1 (KIM-1), serum TNF-α/IL-1β/IL-6 (ELISA), and 7-day survival were assessed. Oxidative stress/ferroptosis was quantified by DCFH-DA ROS imaging and kits (MDA, GSH, SOD, NADPH, Fe, GPX4 activity); TLR4-MyD88-NF-κB by qRT-PCR, Western blot, and Immunohistochemistry. LPS (1 μg/mL, 48 h)-stimulated HK-2 cells underwent shGDF15 lentiviral knockdown (puromycin 2 μg/mL) ± TAK242 (1 μM); viability (CCK-8), apoptosis (Annexin V/PI flow), cytokines (ELISA/qRT-PCR), ROS, ferroptosis markers, and pathway activation were evaluated. GDF15 was upregulated in SAKI datasets, patient kidney tissue, and CLP kidneys. GDF15 supplementation improved survival, lowered Scr/BUN and KIM-1, attenuated tubular injury, and reduced systemic proinflammatory cytokines. It decreased renal ROS, MDA and Fe while restoring GSH, SOD, NADPH, GPX4 activity, and SLC7A11 expression, and suppressed TLR4-MyD88-NF-κB signaling. In HK-2 cells, GDF15 silencing aggravated LPS-induced loss of viability, apoptosis, cytokine release, oxidative stress, and ferroptosis markers, all reversed by TAK242. In conclusion, GDF15 is a stress-inducible renoprotective factor that suppresses TLR4 signaling, ferroptosis markers, and inflammation in SAKI, suggesting exogenous administration as a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.